A number of firms have modified their ratings and price targets on shares of CVRx (NASDAQ: CVRX) recently:
- 8/8/2026 – CVRx was downgraded by Wall Street Zen from “hold” to “sell”.
- 8/7/2026 – CVRx was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $4.00 price target on the stock.
- 8/7/2026 – CVRx was downgraded by Craig Hallum from “buy” to “hold”. They now have a $4.00 price target on the stock.
- 8/7/2026 – CVRx was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $3.50 price target on the stock, down from $14.00.
- 8/3/2026 – CVRx had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 6/27/2026 – CVRx was upgraded by Wall Street Zen from “sell” to “hold”.
CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.
The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.
Featured Stories
- Five stocks we like better than CVRx
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
- Axos Financial Keeps Proving the Digital Banking Model Works
Receive News & Ratings for CVRx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx Inc and related companies with MarketBeat.com's FREE daily email newsletter.
